July 14, 2021 – iRiS Kinetics and axiVEND announced today an agreement to expand their partnership. axiVEND will now assemble iRiS Kinetics MX-100 systems and produce all of the iRiS Chips, all under GMP protocols. In addition, iRiS Kinetics has appointed Claude Dufresne as its Chief Commercialization Officer, with worldwide responsibilities for to market and distribute the product line.

The MX-100 is a compact, low-cost label-free instrument for the measurement of biomolecular affinities. “After an early commercial success, the forecasted demand requires more bandwidth and axiVEND is the perfect partner for us,” said iRiS Kinetics Founder and CEO Selim Ünlü. “A key feature of the MX-100 technology is to perform multiplexed measurements. This enables reliable comparisons of binding affinities. axiVEND’s arraying service capabilities extends our chip production so that we can offer our customers ready-to-use multiplex chips, with custom contents for their needs.”

“From the beginning, coupling the iRiS Technology with our arraying capabilities as been an ideal pairing,” said axiVEND CEO Claude Dufresne PhD. “As the growth for iRiS technology accelerates, it was time to consolidate all of the production and services under one roof. Our new location provides ample space and talent for these activities. We utilize M2-Automation spotters for the best quality arrays possible.”

In contrast to other commercial platforms, iRiS chips can be coated with a very wide range of materials, making them most valuable in getting the best biological performance from immobilized molecules. The liquid flow-through cell in turns provides for true kinetics measurements. Exquisite sensitivity afforded by temporal and spatial averaging allows for the use of a quasi-2D ligand surface allowing for accurate kinetic binding characterization without being obscured by mass-transport limitations through thick and dense hydrogel surface layers common in surface plasmon resonance (SPR) systems.
Applications include measuring binding affinities of small molecules to proteins and biological nanoparticles, useful in drug discovery especially for hit validation, antibody selection for diagnostics or food testing markets, vaccine development, virus neutralization assays, and much more.
The MX-100 is available for purchase now.